We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Three New Next Generation Cardiac Marker Products Launched

By LabMedica International staff writers
Posted on 21 Jul 2010
A Swiss company offers three new cardiac marker test kits for point-of-care (POC) settings. More...


The next generation products are Troponin I--a single-analyte, improved sensitivity Troponin I (TnI) test, Cardio2--a two analyte panel consisting of the new Troponin I and B-type natriuretic peptide (BNP), as well as Cardio3--a three analyte panel consisting of the new Troponin I, BNP and Creatine Kinase, Muscle and Brain (CK-MB).

Alere International (Morges, Switzerland) launched the three new cardiac marker test kits. By offering this improved sensitivity troponin assay on panels that simultaneously test other cardiac markers at the POC, these products will allow emergency physicians to make better chest pain/shortness-of-breath patient disposition decisions much more rapidly.

When used in a rapid serial draw algorithm, the panel results can identify healthy patients earlier, allowing them to go home sooner and physicians to focus their time on only those patients in greatest need. All three products are designed for use on the Triage Meter.

The tests are now available for commercial sale in Europe, Australia, and New Zealand and will soon be available in other countries around the world.

Alere is the new global brand adopted by many of the diagnostic and health management businesses of Inverness Medical Innovations (Waltham, MA, USA).

Related Links:
Alere International
Inverness Medical Innovations





Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.